TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7934600

Group type: EXPERIMENTAL
Intervention: Rapitrac method (blind)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Rapitrac method (fiberoptic bronchoscope)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dissection method
Number of subjects: 55
Study: 3209716

Group type: EXPERIMENTAL
Intervention: brofaromine (BROF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: tranylcypromine (TCP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: unmedicated subjects
Number of subjects: 49
Study: 12362118

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (25-95 units per muscle based on Ashworth score)
Number of subjects: 20
Study: 31362741

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC
Number of subjects: 936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study: 29982723

Group type: EXPERIMENTAL
Intervention: High-Intensity Sweeteners Beverage (HISB) - 2 cans (330 mL each)/d for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unsweetened Beverage (UB) - 2 cans (330 mL each)/d for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-Intensity Sweeteners Beverage (HISB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unsweetened Beverage (UB)
Number of subjects: 60
Study: 27821109

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 68
Study: 23861381

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 53
Study: 22152616

Group type: EXPERIMENTAL
Intervention: PathFile (PF) - NiTi rotary glide path
Number of subjects: 149

Group type: COMPARATOR
Intervention: Stainless-steel K-file (KF) - manual glide path
Number of subjects: 149
Study: 20224007

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain WCFS1 administered in the duodenum for 6 hours via feeding catheter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TLR2 agonist Pam(3)‐Cys‐SK4 (PCSK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum or PCSK
Number of subjects: 0
Study: 17507823

Group type: EXPERIMENTAL
Intervention: Prophylactic antimicrobials limited to <48 hours postoperatively
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Glycopeptides recommended for high-risk patients
Number of subjects: 374

Group type: COMPARATOR
Intervention: No intervention applied
Number of subjects: 374
Study: 16389694

Group type: EXPERIMENTAL
Intervention: Exenatide (glucagon‐like peptide‐1 agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11879382

Group type: EXPERIMENTAL
Intervention: 50 mg LTG
Number of subjects: 30

Group type: COMPARATOR
Intervention: VPA 900 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LTG
Number of subjects: 30

Group type: COMPARATOR
Intervention: VPA
Number of subjects: 30
Study: 10229128

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IgM antibodies to nerve glycoconjugates
Number of subjects: 11
Study: 7887643

Group type: EXPERIMENTAL
Intervention: FP (400 mg/m2 UFT po daily and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: FEP (400 mg/m2 UFT po daily, 50 mg/m2 etoposide iv and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Number of subjects: 48
Study: 2167953

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP; 120 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Carboplatin (CBDCA; 325 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Number of subjects: 228
Study: 598412

Group type: EXPERIMENTAL
Intervention: Digoxin 0.4 mg i.v. daily for 14 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Beta-methyldigoxin 0.4 mg i.v. daily for 14 days
Number of subjects: 5
Study: 31801679

Group type: EXPERIMENTAL
Intervention: TWHF 60 mg/d plus valsartan 160 mg/d
Number of subjects: 124

Group type: COMPARATOR
Intervention: Valsartan 160 mg/d
Number of subjects: 124
Study: 30607527

Group type: EXPERIMENTAL
Intervention: EBP training methods
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Organizational climate
Number of subjects: 200
Study: 28943100

Group type: EXPERIMENTAL
Intervention: Ubiquinol 300mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25858085

Group type: EXPERIMENTAL
Intervention: Gow-Gates (GG) technique
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard technique of inferior alveolar nerve block (IANB)
Number of subjects: 136
Study: 23530837

Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue closure with staples
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue closure with intracutaneous sutures
Number of subjects: 218

Group type: COMPARATOR
Intervention: No subcutaneous tissue closure with staples
Number of subjects: 218

Group type: COMPARATOR
Intervention: No subcutaneous tissue closure with intracutaneous sutures
Number of subjects: 218
Study: 21632811

Group type: EXPERIMENTAL
Intervention: Early metformin (study years 1-4; age 8-12 years)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Late metformin (year 6; age 13-14 years)
Number of subjects: 38
Study: 19492197

Group type: EXPERIMENTAL
Intervention: Polyurethane ChemoSite (AutoSuture)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Polyurethane Port‐a‐Cath (Pharmacia‐Upjohn)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Silicone Port‐a‐Cath
Number of subjects: 228

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 228
Study: 16950076

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 275

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 275
Study: 12589702

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 44)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (Placebo, n = 38)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (Dietary intervention, n = 42)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (Fish oil supplementation + dietary intervention, n = 47)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (n = 80, without fish oil supplementation)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 91)
Number of subjects: 171
Study: 10632907

Group type: COMPARATOR
Intervention: Single injection (Group S)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multiple fractionated doses (Group M)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 8857677

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CCP)
Number of subjects: 100
Study: 1995175

Group type: EXPERIMENTAL
Intervention: 5F catheters via percutaneous right brachial artery approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5F catheters via femoral route
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8F catheters via femoral route
Number of subjects: 60
Study: 6390207

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation unit
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 31255587

Group type: EXPERIMENTAL
Intervention: Glasses
Number of subjects: 119

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 119
Study: 29481640

Group type: EXPERIMENTAL
Intervention: Exercise plus TrP‐DN
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 50
Study: 27669457

Group type: EXPERIMENTAL
Intervention: Physical activity (n=818)
Number of subjects: 1635
Study: 24266598

Group type: EXPERIMENTAL
Intervention: Real-time guidance WED
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Advance guidance WED
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard WED
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 163
Study: 22248749

Group type: EXPERIMENTAL
Intervention: Pituitrin (0.017‐0.042 U/min, 1.0‐2.5 U/h)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 139
Study: 20813217

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Non-adjuvanted influenza vaccine
Number of subjects: 1726
Study: 17410588

Group type: EXPERIMENTAL
Intervention: First-trimester sonographic examinations
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 15846270

Group type: EXPERIMENTAL
Intervention: TEE-guided strategy (n = 544)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Conventional treatment (n = 530)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Overall group data
Number of subjects: 1222
Study: 12224004

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) combined with high-dose arabinosyl cytosine (HDAC)
Number of subjects: 42
Study: 9626770

Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD4 antibody treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study: 8070481

Group type: EXPERIMENTAL
Intervention: Piroximone 5 micrograms.kg‐1.min‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Piroximone 10 micrograms.kg‐1.min‐1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2963533

Group type: EXPERIMENTAL
Intervention: Iron (Fe) supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study: 31160317

Group type: EXPERIMENTAL
Intervention: eGFR decrease ≥40%
Number of subjects: 8766

Group type: EXPERIMENTAL
Intervention: eGFR increase ≥40%
Number of subjects: 8766

Group type: EXPERIMENTAL
Intervention: UACR decrease ≥40%
Number of subjects: 8766

Group type: EXPERIMENTAL
Intervention: UACR increase ≥40%
Number of subjects: 8766

Group type: EXPERIMENTAL
Intervention: eGFR decrease ≥40% and UACR increase ≥40%
Number of subjects: 8766
Study: 27873545

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing Lactobacillus reuteri
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 47
Study: 25678453

Group type: EXPERIMENTAL
Intervention: EG‐1962 (nimodipine microparticles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral nimodipine (active control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EG‐1962
Number of subjects: 0
Study: 24419239

Group type: EXPERIMENTAL
Intervention: Motesanib plus carboplatin/paclitaxel (C/P)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo plus carboplatin/paclitaxel (C/P)
Number of subjects: 227
Study: 21752575

Group type: EXPERIMENTAL
Intervention: 1-day-CPM
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3-day-CPM
Number of subjects: 84

Group type: COMPARATOR
Intervention: no-CPM
Number of subjects: 84
Study: 19011721

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 17703786

Group type: EXPERIMENTAL
Intervention: High evaluation threat
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low evaluation threat
Number of subjects: 72
Study: 14988902

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stents
Number of subjects: 1
Study: 11930611

Group type: EXPERIMENTAL
Intervention: Touch intervention (conducted 2-3 times/day for 15-20 minutes for at least 3 months)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Touch intervention (conducted within one month after birth)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (no touch intervention)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Touch intervention and Control group
Number of subjects: 310
Study: 9039623

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MR imaging with gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA) at a dosage of 0.1 mmol/kg body weight.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dynamic contrast-enhanced MR imaging with Gd-DTPA.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MR imaging follow-up during therapy in patients with B-CLL.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Out-of-phase imaging with Gd-DTPA.
Number of subjects: 75
Study: 7936364

Group type: EXPERIMENTAL
Intervention: NCC-LU-246
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NCC-LU-243
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunocytochemistry with anti-NCAM MAbs
Number of subjects: 40
Study: 3284336

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 47

Group type: COMPARATOR
Intervention: absolute alcohol
Number of subjects: 47
Study: 11100226

Group type: EXPERIMENTAL
Intervention: Type II glass ionomer cement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Microfilled composite resin
Number of subjects: 50
Study: 4812364

Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg per dose for 5 doses
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Percutaneous catheterization
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (open arteriotomy or no aspirin)
Number of subjects: 95
Study: 31491416

Group type: EXPERIMENTAL
Intervention: Postoperative image set
Number of subjects: 210

Group type: COMPARATOR
Intervention: Preoperative image set
Number of subjects: 210
Study: 31512025

Group type: EXPERIMENTAL
Intervention: Heat acclimation (HA) training at 38.0 °C for 10 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Con) training at 20 °C for 10 days
Number of subjects: 22
Study: 28027198

Group type: EXPERIMENTAL
Intervention: Topical anesthetics
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined (1:1 mixture of 1% lidocaine and TA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no anesthetic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine (1% lidocaine)
Number of subjects: 40
Study: 26364532

Group type: EXPERIMENTAL
Intervention: Self-management program applying Dongsasub training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 23884826

Group type: EXPERIMENTAL
Intervention: Ephedrine bolus 5 mg plus ephedrine infusion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ephedrine bolus 5 mg plus normal saline infusion
Number of subjects: 110
Study: 21339543

Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no breathing exercises)
Number of subjects: 60
Study: 19666643

Group type: EXPERIMENTAL
Intervention: candesartan 8 mg/day
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: candesartan 16 mg/day
Number of subjects: 171

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 171
Study: 17850984

Group type: EXPERIMENTAL
Intervention: 4x25 microg GHRH intravenously
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 4x50 microg GHRH intravenously
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 15848527

Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF), prednisone, daclizumab, and reduced CsA dose (5 mg per kg per day for 7 months followed by complete withdrawal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: normal CsA dose (10 mg per kg per day adjusted according to C2 levels), MMF, prednisone, and no daclizumab
Number of subjects: 42
Study: 11548984

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Rebif) 44 mcg subcutaneously three times per week
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Rebif) 22 mcg subcutaneously three times per week
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 9505784

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 60
Study: 8042587

Group type: EXPERIMENTAL
Intervention: H pylori infection
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal histologic characteristics (Control)
Number of subjects: 31

Group type: COMPARATOR
Intervention: H pylori-negative gastritis (Control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: H pylori infection with duodenal ulcers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: H pylori infection without mucosal ulceration
Number of subjects: 31
Study: 3275748

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) to 20 Gy using high‐energy electrons followed by low‐dose (35 to 40 Gy) postoperative external beam irradiation
Number of subjects: 35

Group type: COMPARATOR
Intervention: High‐dose (50 to 55 Gy) postoperative external beam irradiation
Number of subjects: 35
Study: 28222575

Group type: EXPERIMENTAL
Intervention: Self-selected pacing strategy (SSP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Negative pacing strategy (NPS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Even pacing strategy (EPS)
Number of subjects: 15
Study: 27491605

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1480
Study: 25331468

Group type: EXPERIMENTAL
Intervention: Allitridi capsules (120 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 80
Study: 22483593

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial injection with triamcinolone 40mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lidocaine (placebo)
Number of subjects: 58
Study: 20522795

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 23

Group type: COMPARATOR
Intervention: valsartan (160 mg)
Number of subjects: 23
Study: 18042102

Group type: EXPERIMENTAL
Intervention: Polyflex stent (N=47)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ultraflex stent (N=54)
Number of subjects: 101
Study: 16274096

Group type: EXPERIMENTAL
Intervention: Triple-site temporary triggered pacing in the AAT mode at a lower rate of 40 beats/min for 4 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: No pacing (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Triple-site temporary triggered pacing
Number of subjects: 70
Study: 12017396

Group type: EXPERIMENTAL
Intervention: nimesulide-beta-cyclodextrin (400 mg BID, orally = 100 mg nimesulide BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen (500 mg BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nimesulide-beta-cyclodextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 0
Study: 10492407

Group type: COMPARATOR
Intervention: 2% lidocaine and 10 mg preservative-free pethidine (group LP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lidocaine, 10 mg preservative-free pethidine and 20 mg tenoxicam (group LPT)
Number of subjects: 60
Study: 8934067

Group type: EXPERIMENTAL
Intervention: Uniplant contraceptive implant
Number of subjects: 819
Study: 1725913

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6858516

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30413181

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily low-dose antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health economic outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 0
Study: 27435205

Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy
Number of subjects: 2333

Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy
Number of subjects: 2333

Group type: EXPERIMENTAL
Intervention: Prior cerebral infarction
Number of subjects: 2333
Study: 24852946

Group type: EXPERIMENTAL
Intervention: Erythritol candy (7.5 g daily intake)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Xylitol candy (7.5 g daily intake)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Sorbitol candy (7.5 g daily intake)
Number of subjects: 485
Study: 22381809

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tacrolimus and prednisone dual therapy
Number of subjects: 58
Study: 21383479

Group type: EXPERIMENTAL
Intervention: CHX‐free ASF mouthrinse
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CHX mouthrinse
Number of subjects: 42

Group type: COMPARATOR
Intervention: Water
Number of subjects: 42
Study: 17609246

Group type: EXPERIMENTAL
Intervention: IVF treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (age-matched fertile women)
Number of subjects: 50
Study: 16306249

Group type: EXPERIMENTAL
Intervention: Genetic risk assessment program including apolipoprotein E genotype disclosure
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Genetic risk assessment program
Number of subjects: 162
Study: 12075253

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: No symptomatic recurrences of AF
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 264

Group type: COMPARATOR
Intervention: Amiodarone, Sotalol, Propafenone
Number of subjects: 264
Study: 10442959

Group type: EXPERIMENTAL
Intervention: Covered group (22 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (22 patients)
Number of subjects: 44
Study: 7790689

Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Low protein intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Low BUN and less malnutrition at entry
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High blood urea nitrogen (BUN) and high serum creatinine
Number of subjects: 136
Study: 2189328

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50
Study: 110212

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily (A‐50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily (A‐100)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0